Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

GAITHERSBURG, Md., Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M(TM) adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Wednesday, February 28, 2024. Details of the event and replay are as follows:

     Conference call details:



     Date:                    
     February 28, 2024



     Time:                    
     8:30 a.m. U.S. EST



     URL to register phone:                https://emportal.ink/
                                             3SqJSJv



     Dial-in number:            (888) 664-6383 (Domestic) or


                                              (+1) (617) 892-4906
                                                  (International)



     Webcast:                              ir.novavax.com/events

    --  Participants can join the conference call without operator assistance by
        registering and entering their phone number with the above URL to
        receive an instant automated call back.
    --  Participants can also dial direct to be entered into the call by an
        Operator and will be prompted to request to join the Novavax, Inc. call.
    --  To ensure a timely connection, it is recommended that participants join
        at least 10 minutes prior to the scheduled webcast.

      Replay
      details:


     Date:       Available starting at 11:30 a.m. EST, February 28, 2024, until 11:59 p.m. U.S.
                  EST, March 6, 2024


      Dial-
      in
      number:  
     (416) 764-8677 (Domestic) or


                                                 
              (+1) (888) 390-0541 (International)


     Passcode: 
     789473#


     Webcast:  
     
                ir.novavax.com/events, until May 28, 2024

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

View original content:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2023-financial-results-and-operational-highlights-on-february-28-2024-302065938.html

SOURCE Novavax, Inc.